Investigating the role of serotonin in visual orientation processing using an 'ecstasy' (MDMA)-based research model

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 204-212

  Dickson, Clare ^a   Bruno, Raimondo ^a   Brown, John ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b The Australian National University   (Australia)

Author keywords

3,4 Methylenedioxymethamphetamine; Amphetamine; Cannabis; Ecstasy; Lateral inhibition; Occipital lobe; Orientation processing; Serotonin; Tilt aftereffect; Visual perception

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABIS; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG USE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; VISION; VISUAL ORIENTATION;

ADAPTATION, PHYSIOLOGICAL; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; CANNABINOIDS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; ORIENTATION; PHYSICAL STIMULATION; PSYCHOPHYSICS; PSYCHOTROPIC DRUGS; SEROTONIN; TIME FACTORS; VISUAL PERCEPTION; YOUNG ADULT;

EID: 70449496187     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253556     Document Type: Article

References (41)

1. Brown J, Edwards M, McKone E, Ward J: A long-term ecstasy-related change in visual perception. Psychopharmacology 2007; 19: 437-446
2. Harris J, Gelbtuch M, Phillipson O: Effects of haloperidol and nomifensine on the visual aftereffects of tilt and movement. Psychopharmacology 1986; 89: 177-182
3. Masini R, Antonietti A, Moja E: An increase in strength of tilt aftereffect associated with tryptophan depletion. Percept Mot Skills 1990; 70: 531-539
4. Gibson J, Radner M: Adaptation, aftereffect and contrast in the perception of tilted lines. I. Quantitative studies. J Exp Psychol 1973; 20: 453-467
5. Wenderoth P, Smith S: Neural substrates of the tilt illusion. Psychophysiology 1999; 27: 271-274
6. Fusar-Poli P, Allen P, McGuire P, Placentino A, Cortesi M, Perez J: Neuroimaging and electrophysiological studies of the effects of acute tryptophan depletion: A systematic review of the literature. Psychopharmacology 2006; 188: 131-143
7. Green A, Mechan A, Elliot J, O'Shea E, Colado M: The pharmacology and clinical pharmacology of 3,4-methylenedioxyamphetamine (MDMA, 'Ecstasy'). Pharmacol Rev 2003; 55: 463-508
8. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra M, de Wolff F, Booij J: The acute and chronic effects of MDMA ('ecstasy') on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 2002; 26: 387-396
9. McCann U, Szabo Z, Scheffel U, Dannals R, Ricaurte G: Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-1437
10. Fischer C, Hatzidimitriou G, Katz J, Ricaurte G: Reorganisation of ascending serotonin axon projections in animals previously exposed to the recreational drug, 3,4-methylenedioxy- amphetamine. J Neurosci 1995; 15: 5476-5485
11. Ringach D, Shapley R, Hawken M: Orientation selectivity in macaque V1: diversity and laminar dependence. J Neurosci 2002; 22: 5639-5651
12. Harris J, Phillipson O, Watkins G, Whelpton R: Effects of chlorpromazine and promazine on the visual aftereffects of tilt and movement. Psychopharmacology 1983; 79: 49-57
13. Matthews A, Bruno R: Tasmanian Trends in Ecstasy and Related Drug Markets 2006: Findings from the Ecstasy and Related Drugs Reporting System (EDRS). NDARC Technical Report No 281, Sydney, University of New South Wales, 2007
14. Topp L, Barker B, Degenhardt L: The external validity of results derived from ecstasyusers recruited using purposive sampling strategies. Drug Alcohol Depend 2004; 73: 33-40
15. McCann U, Ricaurte G: Amphetamine neurotoxicity: Accomplishments and remaining challenges. Neurosci Biobehav Rev 2004; 27: 821-826
16. Chang L, Alicata D, Ernst T, Volkow N: Structural and metabolic brain changes in the striatum associated with amphetamine abuse. Addiction 2007; 102: 16-32
17. Volz T, Fleckenstein A, Hanson G: Amphetamine- induced alterations in monoamine transport: Implications for neurotoxicity, neuroprotection and treatment. Addiction 2001; 102: 44-48
18. Bowyer J, Frame L, Clausing P, Nagamoto- Combs K, Osterhout C, Sterling C, Tank A: Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharmacol Exp Ther 1998; 286: 1074-1085
19. Volkow N, Chang L, Wang G, Fowler J, Leonido-Yee M, Franceschi D, Sedler M, Gatley S, Hitzemann R, Ding Y, Logan J, Wong C, Miller E: Loss of dopamine transporters in amphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21: 9414-9418
20. Schlicker E, Timm J, Gothert M: Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354: 791-796
21. Kreuz D, Axelrod J: Delta-9-tetrahydrocannabinol: Localization in body fat. Science 1973; 179: 391-392
22. Parrott AC, Gouzoulis-Mayfrank E, Rodgers J, Solowij N: Ecstasy/MDMA and cannabis: The complexities of their interactive neuropsychobiological effects. J Psychopharmacol 2004; 18: 572-575
23. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J: Cannabis and ecstasy/ MDMA (3,4-methylenedioxyamphetamine): An analysis of their neuropsychobiological interaction in recreational users. J Neural Transm 2007; 114: 959-968
24. Morley K, Li K, Hunt G, Mallet P, McGregor I: Cannabinoids prevent the acute hyperthermia and partially protect against the 5- HT depleting effects of MDMA ('Ecstasy') in rats. Neuropharmacology 2004; 46: 954-965
25. Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacology 1998; 139: 261-268
26. Grothenherm F: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360
27. Guilleminault C, Brooks S: Excessive daytime sleepiness: A challenge for the practising neurologist. Brain 2001; 124: 1482-1491
28. Andrews G, Slade T: Interpreting scores on the Kessler Psychological Distress Scale (K10). Aust NZ J Public Health 2001; 25: 494-497
29. Wechsler D: Wechsler Test of Adult Reading. San Antonio, Psychological Corporation, 2001
30. Czermak C, Lehofer M, Gasser-Steiner P, Ettinger S, Lemonis L, Rohrhofer A, Legl T, Liebmann P: Test-retest reliability of a lifetime drug-use questionnaire. Addict Behav 2005; 30: 361-368
31. Darke S, Ward J, Hall W, Heather N, Wodak A: The Opiate Treatment Index (OTI) Manual. Technical report No 11. Sydney, National Drug and Alcohol Research Centre, 1991
32. Saunders J, Aasland O, Babor T, de la Fuente J, Grant M: Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption - II. Addiction 1993; 88: 791-804 (Pubitemid 23194530)
33. Wolfe J, O'Connell K: Fatigue and structural change: Two consequences of visual pattern adaptation. Invest Ophthalmol Vis Sci 1986; 27: 538-543
34. Magnussen S, Johnsen T: Temporal aspects of spatial adaptation: A study of the tilt aftereffect. Vision Res 1986; 26: 661-672
35. Wenderoth P, Johnstone S: The different mechanisms of the direct and indirect tilt illusions. Vision Res 1988; 28: 301-312
36. O'Toole B, Wenderoth P: The tilt illusion: repulsion and attraction effects in the oblique meridian. Vision Res 1976; 17: 367-374
37. Fisk J, Montgomery C, Waering M, Murphy P: The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic? Hum Psychopharmacol Clin Exp 2006; 21: 355-366
38. Hill A: The environment and disease: Association or causation? Proc Royal Soc Med 1965; 58: 296-300
39. Darke S: Self-report among injecting drug users: A review. Drug Alcohol Depend 1998; 51: 253-263
40. Quinn C, Dunn M, Degenhardt L: The illicit tablet market in Victoria, 2004-2007. EDRS Drug Trends Bulletin, December 2007. Sydney, National Drug and Alcohol Research Centre, University of New South Wales, 2007
41. Parrott AC: Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 2004; 173: 234-241